Emergent BioSolutions Announces Fuad El-Hibri to Retire as CEO, Remain as Executive Chairman of the Board of Directors Focused on Corporate Strategy and MA Opportunities

• Published in: Business Wire
• Format: Newsletter
• Language: English
• Published: New York Business Wire 21.12.2011
• Subjects: Acquisitions & mergers; Appointments & personnel changes; Boards of directors; Chairman of the board; Chief executive officers; Chief operating officers; Clinical trials; Leadership; Manufacturing; Presidents; Product development; Regulatory approval; ROCKVILLE, Md

[...] statements are based upon the current beliefs and expectations of management that are subject to risks, uncertainties and other important factors that could cause the Company's actual results to differ materially from those indicated by such forward-looking statements, including appropriations for BioThrax(R) procurement; our ability to obtain new BioThrax(R) sales contracts or modifications to existing contracts; our plans to pursue label expansions and improvements for BioThrax(R); our ability to perform under our current development contracts with the U.S. government; our plans to expand our manufacturing facilities and capabilities, including our ability to develop and obtain regulatory approval for large-scale manufacturing of BioThrax(R) in our large-scale vaccine manufacturing facility in Lansing, Michigan; the rate and degree of market acceptance of our products and product candidates; the success of preclinical studies and clinical trials of our product candidates and post-approval clinical utility of our products; the potential benefits of our existing collaborations and our ability to selectively enter into additional collaborative arrangements; the extent to which our licensing and acquisition activities are complementary to the Company or whether anticipated synergies and benefits are realized within expected time periods; our ability to identify and acquire or in-license products and product candidates that satisfy our selection criteria; ongoing and planned development programs, preclinical studies and clinical trials; the timing of and our ability to obtain and maintain regulatory approvals for our product candidates; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding expenses, future revenue, capital requirements and needs for additional financing; and other factors identified in the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011 and subsequent reports filed with the SEC.\n